Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis by Hogyoung Kim et al.
Kim et al. J Transl Med  (2015) 13:233 
DOI 10.1186/s12967-015-0589-7
RESEARCH
Poly(ADP-ribose) polymerase as a novel 
regulator of 17β-estradiol-induced cell  
growth through a control of the estrogen 
receptor/IGF-1 receptor/PDZK1 axis
Hogyoung Kim1, Abdelmetalab Tarhuni1, Zakaria Y Abd Elmageed2 and A Hamid Boulares1*
Abstract 
Background: We and others have extensively investigated the role of PARP-1 in cell growth and demise in response 
to pathophysiological cues. Most of the clinical trials on PARP inhibitors are targeting primarily estrogen receptor (ER) 
negative cancers with BRCA-deficiency. It is surprising that the role of the enzyme has yet to be investigated in ER-
mediated cell growth. It is noteworthy that ER is expressed in the majority of breast cancers. We recently showed that 
the scaffolding protein PDZK1 is critical for 17β-estradiol (E2)-induced growth of breast cancer cells. We demonstrated 
that E2-induced PDZK1 expression is indirectly regulated by ER and requires IGF-1 receptor (IGF-1R).
Methods: The breast cancer cell lines MCF-7 and BT474 were used as ER(+) cell culture models. Thieno[2,3-c]isoqui-
nolin-5-one (TIQ-A) and olaparib (AZD2281) were used as potent inhibitors of PARP. PARP-1 knockdown by shRNA was 
used to show specificity of the effects to PARP-1.
Results: In this study, we aimed to determine the effect of PARP inhibition on estrogen-induced growth of breast 
cancer cells and examine whether the potential effect is linked to PDZK1 and IGF-1R expression. Our results show that 
PARP inhibition pharmacologically by TIQ-A or olaparib or by PARP-1 knockdown blocked E2-dependent growth of 
MCF-7 cells. Such inhibitory effect was also observed in olaparib-treated BT474 cells. The effect of PARP inhibition on 
cell growth coincided with an efficient reduction in E2-induced PDZK1 expression. This effect was accompanied by a 
similar decrease in the cell cycle protein cyclin D1. PARP appeared to regulate E2-induced PDZK1 at the mRNA level. 
Such regulation may be linked to a modulation of IGF-1R as PARP inhibition pharmacologically or by PARP-1 knock-
down efficiently reduced E2-induced expression of the receptor at the protein and mRNA levels.
Conclusions: Overall, our results show for the first time that PARP regulates E2-mediated cell growth by controlling 
the ER/IGF-1R/PDZK1 axis. These findings suggest that the relationship between ER, PDZK1, and IGF-1R may be per-
turbed by blocking PARP function and that PARP inhibitors may be considered in clinical trials on ER(+) cancers.
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Background
It is well established that estrogen receptor (ER) is 
expressed in the majority of breast cancers and are 
responsive to standard therapy with tamoxifen as the 
leading drug [1]. Despite the success of this therapy, 
reduction of breast cancer recurrence is only by 50% and 
an even lower reduction in mortality rate (~30%) [1, 2]. 
Accordingly, finding new therapeutic targets is urgently 
needed. Achieving this goal requires the identification 
of new players in the complex process of the disease. 
We have recently shown that PDZK1, a scaffold protein, 
plays an important role in estrogen-induced growth of 
breast cancer cells and demonstrated a strong correla-
tion between the expression of the protein and human 
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breast malignancy [3]. We also reported that PDZK1 
gene expression is not a direct product of ER stimula-
tion; rather, it requires the expression and function of 
IGF-1 receptor (IGF-1R) [3]. PDZK1 appears to harbor 
oncogenic activity and promote cell growth by enhanc-
ing EGFR-stimulated MEK/ERK1/2 signaling and IGF-
induced Akt phosphorylation [4]. Interestingly, PDZK1 
plays this important role through stabilization of the 
integrity of Akt, Her2/Neu, and EGFR [4]. The co-chaper-
one Cdc37 appears to play an important role in PDZK1-
mediated stability of Akt [4]. These aforementioned 
findings demonstrated a novel relationship between 
PDZK1, Akt, Her2/Neu, EGFR and Cdc37 in breast can-
cer unraveling a new axis that can be targeted therapeuti-
cally to reduce the burden of human breast cancer.
Poly (ADP-ribose) polymerase (PARP)-1, a member of 
the PARP family of proteins, has initially been described 
as a DNA repair enzyme playing primarily as a regulatory 
protein controlling traffic of DNA repair proteins during 
base excision repair [5, 6]. A prominent function of this 
enzyme is in cell death both as an effector and as a sub-
strate to some of the caspases [7]. We demonstrated many 
years ago that cleavage of PARP-1 is critical for the nor-
mal progression of the apoptotic process and that inter-
ference with such cleavage enhances cell death and may 
even cause a switch to necrosis [7, 8]. Increasing evidence 
from our laboratory and many others demonstrate an 
important role for this enzyme in tissue injury associated 
with oxidative stress and inflammation including asthma 
and atherosclerosis [8–13]. PARP-1 is thought to partici-
pate in inflammation by regulating the expression of sev-
eral inflammatory factors including adhesion molecules, 
TNF-α, interleukins, and inducible nitric oxide synthase 
(iNOS) most of which are controlled by NF-κB (4). PARP 
inhibitors have shown great potential against breast and 
ovarian cancers especially those with BRCA mutations 
[14]. The combination of PARP inhibitors with DNA dam-
aging chemotherapeutic drugs have shown to induce the 
specific demise of BRCA-deficient cancer cells leading to 
a synthetic lethality phenotype while sparing the life of 
normal cells [15]. Many clinical trials have demonstrated 
efficacy of PARP inhibitors and their potential as thera-
peutic strategy that can be utilized in the clinic [14, 15]. 
However, the focus on BRCA-deficient breast cancer pre-
vented the examination of the effects of PARP inhibitors 
on ER positive breast cancer cells and, as a result, may be 
reducing the full therapeutic potential of these drugs.
In the present study we wished to determine the effect 
of PARP inhibition pharmacologically or PARP-1 knock-
down on estrogen-induced growth of the ER positive 
breast cancer cell line MCF-7 and BT474 and to examine 
whether the potential effect was related to a modulation 
of E2-induced PDZK1 expression.
Methods
Materials
DMEM, penicillin, streptomycin, and fetal bovine serum 
(FBS) were purchased from Invitrogen (Camarillo, CA, 
USA). Charcoal/dextran-treated FBS (CDSS) was pur-
chased from Hyclone (Logan, Utah, USA); 17β-Estradiol 
(E2), and the PARP-1 inhibitor TIQ-A were from Sigma-
Aldrich (St. Louis, MO, USA); olaparib (AZD2281) was 
from Selleckchem (Pittsburgh, PA, USA); IGF-1R inhibi-
tor AG1024 was from Calbiochem (San Diego, CA, USA); 
PARP-1 and PDZK-1 shRNA expressing lentiviral vectors 
and the control virus were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Unless otherwise indicated, 
all other drugs were purchased from Sigma-Aldrich.
Cell culture, cell proliferation, cell survival, transfection, 
immunoblot analysis, and RT‑PCR
The ER positive breast Cancer cell line MCF-7 was 
obtained from ATCC (Manassas, VA, USA). The second 
ER positive breast cancer cell line BT474 was originally 
obtained from ATCC but provided by Dr. Wanguo Liu 
(LSUHSC). The two cell lines were cultured according to 
ATCC instructions. These cell lines are authenticated by 
ATCC using short tandem repeat (STR) profiling. This 
PCR-based approach permits the authentication of human 
cell lines with high resolution down to the individual donor. 
Upon receipt from ATCC, the morphology was confirmed 
by microscopy and population-doubling times were deter-
mined using the trypan blue dye exclusion method. After 
cells reached 70% confluence, complete DMEM medium 
was changed to DMEM supplemented with 5% CDSS 
followed by E2 (1  nM) treatment for the indicated time 
periods. Cells were also treated with TIQ-A, olaparib, or 
AG1024. Cell proliferation was measured by MTT assay 
after 2  days of treatment as previously described [3]. In 
some experiments, cells were transduced with a lentiviral 
vector encoding control shRNA or shRNA targeting human 
PARP-1 or PDZK1 (Santa Cruz Biotechnology) accord-
ing to the manufacturer’s instructions. Cells were selected 
with puromycin dihydrochloride (Santa Cruz Biotechnol-
ogy) and treated as described above. After the treatments, 
cells were collected and subjected to total RNA or protein 
preparation. Isolated RNA was reverse-transcribed and the 
resulting cDNA was subjected to conventional or quantita-
tive PCR with primer sets purchased from IDT (San Jose, 
CA, USA) specific to human PDZK1, IGF-1R and β-actin 
as described [3]. Protein extracts were subjected to immu-
noblot analysis with antibodies to PDZK1 (EPR3751 clone) 
(Novus Biological), PARP-1 (BD Biosciences, San Jose, CA), 
cyclin D (Santa Cruz Biotechnology) or GADPH (Santa 
Cruz Biotechnology). The immunoblots were incubated 
with the appropriate secondary antibodies and signals were 
detected by ECL (Pierce, Rockford, IL, USA).
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Statistical analysis
Data are presented as mean ± SEM from at least three sep-
arate experiments. Comparisons between multiple groups 
were performed with one-way ANOVA with Bonferroni’s 
test using GraphPad software, Version 5 (La Jolla, CA, 
USA). Statistical significance was considered at p < 0.05.
Results and discussion
PARP inhibition blocks E2‑dependent growth of MCF‑7 cells
Figure  1a shows that PARP inhibition with the specific 
inhibitor TIQ-A exerted no effect on the growth of the 
breast cancer cell line MCF-7 except at a very high concen-
tration of 50 μM. This result is consistent with our previous 
report which concluded that the growth inhibition caused 
by the high concentrations of PARP inhibitors is most likely 
associated with toxicity of the drugs rather than an effect 
related to PARP inhibition [16, 17]. However, it is now 
established that PARP inhibition causes cell death when 
combined with BRCA deficiency [18]. It is rather surprising 
that the role of PARP in estrogen-mediated growth of 
breast cancer cells has not been investigated. We thus 
wished to examine whether PARP-1 plays a role in growth 
mediated by E2. Figure  1b shows that E2 treatment, as 
expected, induced ~40% increase in growth of MCF-7 cells, 
which is typical as reported by our laboratory and others 
[3, 19]. PARP inhibition by TIQ-A blocked E2-induced 
growth of MCF-7 cells even at a concentration as low as 
0.5 μM. The specificity of this effect was confirmed using 
a PARP-1 shRNA-mediated knockdown approach (Fig-
ure 1c, d). These results clearly show that PARP plays a role 
in E2-mediated cell growth and that its inhibition can be 
regarded as a means to block abnormal proliferation of ER 
positive breast cancer cells. Such inhibition was achieved 
with rather low concentrations of the PARP inhibitor. Our 
results show that in addition to the ability of PARP inhibi-
tor to promote a synthetic lethality phenotype in BRCA-
deficient cells [18], it can also reduce E2-dependent growth 
in ER positive tumor cells.
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Figure 1 Effect of PARP inhibition on E2-stimulated growth of MCF-7 cells. a MCF-7 cells were treated for 48 h in the absence or presence of 
increasing concentrations of TIQ-A. Cell viability was assessed using a MTT assay. ¶Difference from viability values of cells that did not receive TIQ-A; 
p < 0.05. b MCF-7 cells were stimulated with 1 nM E2 for 48 h in the absence or presence of the indicated TIQ-A concentrations. Cell viability was 
then assessed using a MTT assay. ¶Difference from viability values of cells that did not receive TIQ-A; p < 0.05. §Difference from viability values of 
cells that were treated with E2 alone; p < 0.05. c MCF-7 cells were transduced with a viral vector encoding control shRNA or a shRNA targeting 
human PARP-1. Protein extracts were prepared and subjected to immunoblot analysis with antibodies against PARP-1 or GAPDH. d Cells expressing 
control or PARP-1-targeting shRNA were treated with E2 for 48 h after which viability was assessed as described above. 
¶Difference from respective 
untreated controls; § difference from E2-treated cells; p < 0.05.
Page 4 of 9Kim et al. J Transl Med  (2015) 13:233 
PARP inhibition‑associated reduction in E2‑induced growth 
of MCF‑7 cells is linked to a reduction in PDZK1 expression 
with a concomitant decrease in cyclin D1
We recently showed in two detailed studies that 
E2-mediated cell growth can be governed by PDZK1 [4]. 
We thus speculated that PARP-1 may be involved in ER-
mediated growth of MCF-7 cells potentially through a 
control of PDZK1 expression. As reported previously [3] 
and as shown in Figure 2a, knockdown of PDZK1 blocks 
growth of MCF-7 cells in response to stimulation with 
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Figure 2 Effect of PARP inhibition on E2-stimulated expression of PDZK1 and cyclin D1. a MCF-7 cells were transduced with a viral vector encoding 
control shRNA or a shRNA targeting human PDZK1. Cells were then treated with E2 for 48 h after which cell viability was assessed. 
¶Difference from 
untreated controls; §difference from E2-treated cells; p < 0.05. b Cells were treated with E2 for 48 h after which protein extracts were prepared and 
subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, PARP-1, or GAPDH. c Cells were treated with E2 for 48 h in the absence or 
presence of increasing concentrations of TIQ-A. Protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, 
cyclin D1, or GAPDH. d MCF-7 cells were transduced with a viral vector encoding control shRNA or a shRNA targeting human PARP-1. Cells were 
then treated with E2 for 48 h after which protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, 
PARP-1, or GAPDH.
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1 nM of E2. We next wished to examine whether PARP-1 
enzymatic activity or protein expression influences E2-
induced PDZK1 expression. To this end, MCF-7 cells 
were exposed to E2 for 48 h in the absence or presence 
of increasing concentrations of TIQ-A. Immunoblot 
analysis of collected cell extracts showed that PARP 
inhibition was very efficient in reducing expression of 
PDZK1 (Figure 2b, c). The results also show that partial 
reduction of PDZK1 by 0.5 μM TIQ-A was sufficient to 
completely block E2-induced growth of MCF-7 cells (as 
shown in Figure  1b). These results are consistent with 
our previous observation that partial knockdown of E2-
induced PDZK1 was sufficient to completely block E2-
induced growth of MCF-7 cells [3]. The involvement of 
PDZK1 in growth of MCF-7 cells appears to be linked 
to expression of cyclin D1 as knockdown of PDZK1 pre-
vents E2-induced expression of the cell cycle protein [3, 
4]. Although it is unlikely that PARP is always required 
for the expression of cyclin D1, it was recently reported 
that the expression of the enzyme as well as its activity 
are required for cyclin D1 expression in response to 
ectopically-expressed Krüppel-like factor 8 (KLF8) [20]. 
An additional link between PARP-1 and cyclin D1 is 
the relationship of both proteins to NF-κB. We and oth-
ers have shown that PARP-1 plays an important role in 
NF-κB function [21, 22]. Furthermore, cyclin D1 expres-
sion can be controlled by NF-κB [23]. We next exam-
ined whether the role of PARP-1 in PDZK1 expression 
influences expression of cyclin D1 upon E2 exposure. 
Figure  2d shows that PARP inhibition with TIQ-A 
reduced cyclin D1 expression in a manner similar to that 
exerted on PDZK1. Additionally, knockdown of PARP-1 
markedly reduced expression of PDZK1 and cyclin D1 
showing the specificity of the effect (Figure  2d). It is 
noteworthy that an increase in PDZK1 expression in 
response to E2 treatment did not change the levels of 
PARP-1 (Figure  2d). This is consistent with our pub-
lished results showing that ectopic PDZK1 expression 
in the absence of E2 exposure does not affect expression 
of PARP-1 [4]. Although these results do not prove that 
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Figure 3 Effect of PARP inhibition on PDZK1 mRNA in E2-stimulated MCF-7 cells. MCF-7 cells were treated with E2 for 24 h in the absence or pres-
ence of 1 or 2 μM TIQ-A. Total RNA was prepared and subjected to reverse transcription followed by conventional (a) or quantitative (b) PCR with 
primers specific to human PDZK1 or β-actin. ¶Difference from untreated controls; §difference from E2-treated cells; p < 0.05. c MCF-7 cells were 
transduced with a viral vector encoding control shRNA or a shRNA targeting human PARP-1. Cells were then treated with E2 for 24 h after which 
total RNA was prepared and subjected to conventional RT-PCR with primers specific to human PDZK1 or β-actin.
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E2 exposure does not affect the activity of PARP, we can, 
however, conclude that it does not change the expression 
levels of this DNA repair enzyme.
PARP regulates E2‑induced PDZK1 at the mRNA level
We have shown previously that PARP-1 may control 
expression of a number of proteins by regulating their 
expression at the mRNA level or by influencing their sta-
bility. For instance, PARP-1 regulates expression of sev-
eral inflammatory proteins including adhesion molecules, 
iNOS, TNF-α, IL-1β, IL-5, and IL-13 [12, 24, 25]. PARP-1 
may also regulate proteins at the level of their integrity. 
Indeed, PARP-1 influences the fate of STAT-6 upon IL-4 
or allergen exposure by preventing the degradation of 
the transcription factor by calpains [26]. We therefore 
wished to determine whether PARP-1 regulates expres-
sion of PDZK1 at the level of mRNA. Figure 3a shows that 
PARP inhibition was very effective in blocking E2-medi-
ated increase in PDZK1 transcript. The effect of the PARP 
inhibitor on expression of E2-induced PDZK1 mRNA was 
confirmed by quantitative RT-PCR (Figure  3b). Consist-
ent with these results, PARP-1 knockdown was equally 
efficient in blocking E2-mediated increase in PDZK1 
mRNA (Figure 3c). These results suggest that PARP-1 may 
regulate PDZK1 expression at the level of mRNA. How-
ever, it is premature to conclude that it influences its gene 
transcription. Given the lack of evidence for the control of 
PDZK1 by proteolysis, it is unlikely that PARP-1 regulates 
the protein by influencing its integrity.
PARP‑1 regulates E2‑mediated growth of MCF‑7 cells 
and PDZK1 expression by controlling the expression 
of IGF‑1R
We reported that PDZK1 expression was indirectly regu-
lated by ER-α activation, requiring IGF-1R expression 
and function [3]. Blocking the activity of IGF-1R by the 
specific inhibitor AG1024 blocked E2-induced PDZK1 in 
MCF-7 cells (Figure 4a). We thus speculated that PARP-1 
may be regulating PDZK1 expression through IGF-1R. 
Indeed, PARP-1 inhibition with TIQ-A reduced expres-
sion of E2-induced IGF-1R even at the lowest concentra-
tion (Figure  4b). Figure  4c shows that PARP inhibition 
efficiently blocked E2-induced expression of IGF-1R 
mRNA in MCF-7 cells. PARP-1 knockdown almost com-
pletely blocked the expression of E2-induced IGF-1R (Fig-
ure  4d) confirming the results attained using the PARP 
inhibitor and demonstrating specificity of the effect.
PARP inhibition by olaparib (AZD2281) blocks E2‑mediated 
growth of MCF‑7 and BT474 cells and inhibits expression 
of PDZK1 and IGF‑1R
An important step in proving the validity of targeting 
PARP to control growth of ER(+) breast cancer cells is 
to demonstrate that PARP inhibitors other than TIQ-A 
can achieve the same effect and to show that such effect 
is observed in breast cancer cells other than MCF-7 
cells. Olaparib (AZD2281), a potent PARP inhibitor, is 
currently used in a large number of clinical trials target-
ing BRCA(−) breast and ovarian cancers [15]. We thus 
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Figure 4 PARP inhibition reduces E2-induced IGF-1R. a MCF-7 cells 
were treated with E2 for 48 h in the absence or presence of 1 or 2 μM 
of the IGF-1R inhibitor AG1024 after which protein extracts were 
prepared and subjected to immunoblot analysis with antibodies to 
PDZK1 or GAPDH. b Cells were treated with E2 for 48 h in the absence 
or presence of increasing concentrations of TIQ-A. Protein extracts 
were prepared and subjected to immunoblot analysis with antibod-
ies to IGF-1R or GAPDH. c MCF-7 cells were treated with E2 for 24 h 
in the absence or presence of 0.5, 1, 2 or 5 μM TIQ-A. Total RNA was 
prepared and subjected to reverse transcription followed by conven-
tional PCR with primers specific to human IGF-1R or β-actin. d MCF-7 
cells were transduced with a viral vector encoding control shRNA or 
a shRNA targeting human PARP-1. Cells were then treated with E2 
for 48 h after which protein extracts were prepared and subjected 
to immunoblot analysis with antibodies to PARP-1, PDZK1, IGF-1R, or 
GAPDH. The dashed line indicates that the lane was cut from the same 
blot.
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tested the effect of different concentrations of olaparib 
on growth of MCF-7 cells. Figure  5a shows that olapa-
rib at the 5 μM concentration partially but significantly 
reduced E2-induced cell growth; the 10  μM concentra-
tion of the drug completely blocked growth of the treated 
cells. Figure 5b shows that olaparib was very effective in 
blocking growth of BT474 cells, another ER(+) cell line 
[27].
We next examined whether growth inhibition of 
MCF-7 cells by olaparib correlated with a decrease in 
PDZK1, cyclin D1 and IGF-1R. Figure  5c clearly shows 
that olaparib treatment markedly blocked expres-
sion of E2-induced PDZK1 in a manner similar to that 
achieved by TIQ-A. Such inhibition of PDZK1 expres-
sion occurred concomitantly with a reduction in cyclin 
D1 and IGF-1R upon exposure to E2 in MCF-7 cells. Fig-
ure 5d shows that PARP inhibition reduces PDZK1 and 
IGF-1R at the level of mRNA. Overall, these results are 
consistent with those attained using TIQ-A as a PARP 
inhibitor and demonstrate that the ability of PARP inhibi-
tion to block E2-induced growth is not limited to TIQ-A 
or MCF-7 cells but may be extended to other ER(+) 
breast cancer cells.
Conclusions
It is well recognized that breast and ovarian cancer het-
erogeneity continues to represent a major obstacle in 
tailoring precise and efficient therapies with minimal 
toxicities. Much effort is needed to identify key deter-
mining factors that control the growth of cancer cells. 
Accordingly, insights on the role of new factors or iden-
tification of new functions for already established players 
may provide us with new directions and strategies with 
which cancer can be retarded or blocked. Collectively, 
our results suggest that PARP may play an important role 
in E2-induced cell growth by regulating the expression of 
PDZK1 through a control of the stimulated expression 
of IGF-1R. To our knowledge, our results are the first in 
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Figure 5 Olaparib treatment blocks E2-mediated growth of MCF-7 and BT474 cells and inhibits expression of PDZK1, IGF-1R, and cyclin D1. MCF-7 
(a) or BT474 (b) cells were stimulated with 1 nM E2 for 48 h in the absence or presence of the indicated olaparib concentrations. Cell viability was 
then assessed using a MTT assay. ¶Difference from viability values of cells that did not receive olaparib; p < 0.05. §Difference from viability values of 
cells that were treated with E2 alone; p < 0.05. c MCF-7 cells were treated with E2 for 48 h in the absence or presence of increasing concentrations of 
olaparib after which protein extracts were prepared and subjected to immunoblot analysis with antibodies to PDZK1, cyclin D1, IGF-1R, or GAPDH. 
d MCF-7 cells were treated with E2 for 24 h in the presence of 5 μM olaparib. Total RNA was prepared and subjected to reverse transcription fol-
lowed by quantitative PCR with primers specific to human PDZK1, IGF-1R or β-actin. §Difference from E2-treated cells; p < 0.05.
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showing a connection between PARP and ER-stimulated 
growth and that such trait may be considered in the cur-
rent effort in establishing PARP inhibitors in the treat-
ment of breast and ovarian cancers. We have shown a 
strong relationship between PDZK1 and IGF-1R expres-
sion in human breast cancer and that PDZK1 may be a 
determinant in breast tumorigenesis [3, 4]. The molecu-
lar link between PDZK1 and IGF-1R was supported by a 
significant correlation between protein and mRNA levels 
of the two factors in two independent cohorts of human 
breast cancer tissues [3].
The current results suggest that the relationship 
between ER, PDZK1, and IGF-1R may be an appeal-
ing axis to be targeted by PARP inhibitors. It is note-
worthy that a great deal of effort is being spent focusing 
primarily on triple negative breast and ovarian cancers 
with a BRCA deficiency to specifically achieve synthetic 
lethality of cancer cells with the BRCA mutation [28]. 
Although the presented results do not provide a com-
plete understanding of the mechanism by which PARP 
regulates PDZK1 or IGF-1R, they support the hypothesis 
that PARP inhibitors, including olaparib, may be useful 
for treatment of ER(+) and estrogen-dependent cancers. 
Obviously, more work is needed to validate such hypoth-
esis and unravel the molecular mechanisms underlying 
the cross-talk between the different factors.
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